Jim Heppell BSc, LLP
Mr. Heppell is the co-founder, president and a director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Early in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd.), Immgenics (acquired by Amgen), Inovio Pharmaceuticals, and Sophiris Bio Inc. He earned a BSc in microbiology and a law degree from the University of British Columbia.